Solventum Q1 2026 sales fall 3.0% to $2.0 billion; adjusted EPS rises 10.6% to $1.48
Solventum reported first-quarter 2026 results on May 5, 2026, with net sales down 3.0% to $2.0 billion on a reported basis and up 2.1% on an organic basis. GAAP diluted EPS fell to $0.07 from $0.78, while adjusted diluted EPS rose 10.6% to $1.48. The company affirmed its full-year 2026 organic sales growth and free cash flow guidance and said adjusted EPS is estimated to be toward the high end of its $6.40 to $6.60 range.
Key points
- Reported sales of $2.0 billion, down 3.0% from $2.07 billion a year earlier; organic sales up 2.1%
- GAAP net income of $13 million versus $137 million, with separation and restructuring costs weighing on results
- Adjusted diluted EPS of $1.48 versus $1.34; free cash flow was negative $273 million
- Full-year 2026 guidance affirmed, with free cash flow of about $200 million and adjusted EPS toward the high end of $6.40 to $6.60
The filing
Written by AI on Nov 8, 2026, 1:11 AM ET, from this filing only. Written later: this filing was briefed after the fact, when past filings were added to the site, so the brief may be read with hindsight; the filing itself is the record of what was known on May 05, 2026.
Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.